Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of Fidarestat (cas 136087-85-9) by ultra high performance liquid chromatography–high resolution mass spectrometry

Add time:08/31/2019    Source:sciencedirect.com

Fidarestat (cas 136087-85-9), an aldose reductase inhibitor, has been used for the treatment of the diabetic associated complications such as retinopathy, neuropathy and nephropathy. To better understand the metabolism and pharmacokinetics of fidarestat, we have evaluated plasma protein binding, pharmacokinetics, tissue distribution of the drug and its conjugated metabolites and CYP450 biotransformation by liquid chromatography–high resolution mass spectrometry. Effective chromatographic separation of fidarestat and hydrochlorothiazide (IS) in rat plasma and tissues was achieved on Hypersil gold C-18 column in an isocratic elution mode. For detection, a high-resolution Orbitrap mass spectrometer with heated electrospray ionization inlet in the negative ion mode was used. High-resolution extracted ion chromatograms for each analyte were obtained by processing the full-scan MS mode with 5 ppm mass tolerance. The impact of plasma protein binding with the drug and conjugated metabolites of the drug on pharmacokinetics has been determined. The study indicated that 9.5% of free form of fidarestat may be pharmacologically active and the Cmax for free fidarestat was found to be 80.30 ± 6.78 ng/mL. The AUC0–t and AUC0–∞ were found to be 185.46 ± 32 and 195.92 ± 15.06 ng h/mL, respectively. Among tissues, the maximum observed distribution was found to be in kidney followed by liver and heart. Docking experiments and in vitro CYP450 reaction phenotyping revealed that two CYP1A2 and CYP2D6 are involved in the phase I metabolism of fidarestat. Oxidative deamination and N/O glucuronidation are the major phase I and phase II metabolites, respectively. In vitro CYP450 inhibition assay of fidarestat for drug–drug interaction showed weak inhibition and may not alter pharmacokinetics, distribution or clearance of other co-administered drug.

We also recommend Trading Suppliers and Manufacturers of Fidarestat (cas 136087-85-9). Pls Click Website Link as below: cas 136087-85-9 suppliers

Prev:X-ray structure of the V301L aldo–keto reductase 1B10 complexed with NADP+ and the potent aldose reductase inhibitor Fidarestat (cas 136087-85-9): Implications for inhibitor binding and selectivity
Next:Fidarestat (cas 136087-85-9) (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients)